ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Says New Russian Drug Factory Ready In Two Years

By Tracy Corrigan Novartis AG's (NVS) new $150 million manufacturing plant outside St Petersburg will be built in two years, Joseph Jimenez, chief executive officer of the Swiss pharmaceuticals company said. All the building permits are in place. Registration and certification of the site will be required before production starts, he added. In an interview at the St Petersburg International Economic Forum, Jimenez, an American, described the project as a "substantial" investment. In late 2010, Novartis announced it would invest $500 million in Russia over the next five years, in an attempt to strengthen its position there. That followed warnings from the country's prime minister at the time, Vladimir Putin, that global pharmaceutical companies would face restrictions if they failed to establish manufacturing facilities and transfer technology to the country. Putin has since been re-elected as Russia's president. Many pharmaceuticals companies currently export to Russia but "the government has been very clear that over time they will face hurdles" in the form of tariffs, Mr Jimenez noted. That reflects Russia's aim to reduce its dependence on imported drugs. Novartis is already the largest foreign operator in the Russian pharmaceuticals market, its CEO told Dow Jones. "This government really wants to attract foreign investment," he added. It has offered tax incentives and infrastructure support in economic zones to encourage foreign pharmaceuticals companies to start manufacturing on Russian soil. The Russian government exerts control over the sector through import duties, subsidized purchases of drugs for people with low-incomes, and funding purchases of medical equipment for hospitals. Novartis expects the Russian pharmaceuticals market to grow at an annual rate of 7 per cent in the next few years, assuming the economy continues to expand at around 4-5 per cent annually. The healthcare market is growing faster, partly because of the government's commitment to increase life expectancy, which will involve increasing the number of diseases for which treatment costs are reimbursed by the state, according to Mr Jimenez. Novartis will also increase the number of clinical trials it conducts in Russia, as well as collaborating on research with Russian universities. The company is also involved in a number of public health projects. Novartis's global clinical standards apply in Russian trials, Mr Jimenez said. Commenting on the euro zone crisis, Mr Jimenez said Novartis is being "very conservative in how we are managing cash" in some euro zone countries and is working to reduce receivables from hospitals in those countries. He added that in extreme cases, Novartis has not cut off shipments of life-saving medications. "We are working with these governments", he said. Write to Tracy Corrigan at

Stock News for Novartis (NVS)
11/25/201511:30:00Prescription Skin Drugs Explode in Costs, Study Shows
11/23/201509:20:02The FDA Approves Exelixis, Inc's New Cancer Drug
11/23/201508:46:033 Dividend Stocks You Don't Have to Babysit
11/20/201517:35:00Novartis Finalizes Settlement With Justice Department
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/19/201509:16:045 Things GlaxoSmithKline PLC Wants You to Know
11/17/201511:40:56Why Ophthotech Corporation's Shares Soared in October
11/07/201513:40:09Momenta Slowed (Temporarily)
11/06/201512:16:03Why XOMA Shares Are Crashing
11/04/201510:20:02Is This Drug Going to Be a Big Threat to Biogen and Novartis...
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/31/201509:21:03Generic Copaxone Isn't Derailing Teva Pharmaceuticals...Yet
10/29/201516:07:02GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery
10/28/201509:20:00GlaxoSmithKline Sees Higher Sales
10/28/201509:03:00GlaxoSmithKline Sees Higher Sales in Third Quarter But Lower...
10/27/201511:15:00Novartis Profit Hurt by U.S. Settlement -- 4th Update
10/27/201507:49:00Novartis Profit Hurt by U.S. Settlement-- Third Update
10/27/201505:50:00Global Stocks Fall Ahead of Fed Meeting
10/27/201505:05:00Novartis Profit Hurt by U.S. Settlement -- 2nd Update
10/27/201504:57:00Novartis Profit Hurt by U.S. Settlement -- Update

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations